It has been only in the last few years [96] that other immunotherapies have regained interest, not just against PSMA but also anti-PSA, anti-PAP, anti-PSCA, or other more general tumor associated antigens such as B7-H3 [97] or Epithelial Cell Adhesion Molecule (EpCAM) precursor [94]. Here, FOLH1 is linked to neoplasm.